News & Press Releases - 2017
Incysus Announces Appointment of Siraj Ali, MD, PhD to its Scientific Advisory Board
November 30, 2017
Incysus announced the addition of Siraj Ali, MD, PhD to its Scientific Advisory Board (SAB). Dr. Ali is a physician-scientist and leads translational research efforts at Foundation Medicine. He focuses on identifying predictive biomarkers for targeted anti-neoplastic and cancer immunotherapies, which encompasses both basic cancer biology and exceptional responders in the clinic.
Incysus Announces FDA Clearance of IND Application for a Phase I Study of a Gamma-Delta (γδ) T Cell Leukemia and Lymphoma Immunotherapy
October 17, 2017
Incysus announced the clearance of an investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA) allowing the initiation of a Phase I clinical trial testing the allogeneic delivery of expanded and activated gamma-delta (γδ) T cells for the treatment of patients with blood cancers following haploidentical stem cell transplantation.
CHEMO-PROOF T CELLS - By Lauren Martz, Senior Writer, BioCentury
October 12, 2017
Incysus and our innovative technology were profiled in the October 12, 2017 edition of BioCentury Innovations.
Incysus Submits Investigational New Drug (IND) Application for Allogeneic Gamma-Delta T Cell Immunotherapy for Leukemia and Lymphoma
September 19, 2017
Incysus today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a first-ever Phase I study of expanded and activated gamma-delta (γδ) T cells for the treatment of patients with blood cancers following haploidentical stem cell transplantation.
Incysus Collaborators Publish Review in Bone Marrow Transplantation
September 7, 2017
Incysus’ scientific co-founder Dr. Lawrence S. Lamb, PhD and collaborator Dr. Ayman Saad, MD at the University of Alabama at Birmingham (UAB) published in print a review of current and emerging strategies of T cell depletion in allogeneic hematopoietic stem cell transplantation in the journal Bone Marrow Transplantation.
Incysus Announces Formation of Scientific Advisory Board
August 24, 2017
Incysus announces the formation of its inaugural Scientific Advisory Board (SAB) with a world-leading group of experts in the areas of immunology, cell therapy and oncology.
Incysus Scientific Co-Founder to Present at Immuno-Oncology Summit
August 23, 2017
Incysus’ collaborator and scientific co-founder, Dr. Lawrence S. Lamb, MN, PhD from the University of Alabama at Birmingham (UAB), will be presenting at the Immuno-Oncology Summit in Boston on Wednesday, August 30th, 2017 (https://immuno-oncologysummit.com/T-Cell/).
UAB spinoff targets cancer with drug-resistant immunotherapy, a novel approach to fighting tumors
May 4, 2017
The University of Alabama at Birmingham (UAB), Emory University and Children’s Healthcare of Atlanta have licensed technology to Incysus to develop a novel cellular therapy called Drug-Resistant Immunotherapy or DRI.
Incysus Granted European Patent Covering its Drug Resistant Immunotherapy (DRI) Technology
April 12, 2017
The European Patent Office granted EU Patent No. 2496244 covering claims related to methods of combining chemotherapy with immunotherapy.
Incysus Announces Preclinical Data Presentations of γδ T Cell Immunotherapy Programs at Upcoming Medical Conferences
March 24, 2017
Incysus’ academic collaborators present preclinical data highlighting their γδ T cell immunotherapy programs at major medical conferences.